We live in times of unlimited possibilities. The development of theologies is lightning fast. Inventions in medicine are also opening up new possibilities in the treatment of many diseases at a rapid pace. The H2MEDICAL team has been greatly impressed by a number of scientific publications pointing to Photobiomodulation (PBM) as an innovative method in the treatment of many diseases. The ability of FBM to stimulate the activity of mitochondria and prevent their atrophy leads to the restoration of cellular activity and tissue regeneration. The therapeutic effect of taking hydrogen gas dissolved in water (hydrogen water) in turn has the ability to protect the body from the side effects of PBM. Below we have posted the Introduction (Abstract) of a clinical study of Parkinson's Disease patients published on January 29, 2021. They were subjected to combined treatment with FBM and H2 water intake. Its title is also a link that will take you to the full official medical report and our translated Abstract.
Parkinson's disease (PD), the second most common neurodegenerative disorder, has no cure or feasible approach to disease modification, only symptomatic therapy. Oxidative stress and mitochondrial dysfunction play a key role in the pathophysiology of PD. Animal studies have demonstrated that photobiomodulation (PBM) can improve mitochondrial function and stimulate adenosine triphosphate production, thereby alleviating symptoms from Parkinson's disease; however, this process can lead to increased production of reactive oxygen species (free radicals). Molecular hydrogen (H2) is a powerful therapeutic antioxidant that can eliminate the effects of free radicals. Photobiomodulation targeted to the brainstem can stimulate neuronal activity and the concomitant intake of hydrogen gas dissolved in water (H2 water) can scavenge the free radicals formed by the administration of FBM. Therefore, this study aims to determine the safety and effectiveness of combining FBM therapy + H2 therapy in patients with Parkinson's disease.
We enrolled 18 PD patients (aged 30-80 years) who were in Hoehn and Yahr stages II-III. All participants received daily FBM therapy + H2 therapy for 2 weeks. Possible adverse effects and Unified Parkinson's Disease Rating Scale (UPDRS) scores were reported.
We noted that the USOBP scores started to significantly decrease from the first week and this improvement continued until the end of therapy. Furthermore, no adverse effect of therapy was recorded. After 1 week of stopping therapy, the USOP scores increased slightly, but the improvement remained significant compared to the patients' baseline.
This new proof-of-concept study demonstrates that therapy with FBM + H2 intake is safe and reduces disease severity. A larger clinical trial is planned to fully investigate the effects of FBM + H2 therapy on Parkinson's disease.
In early 2021, the H2MEDICAL team added the Swiss Bioptron Pro1 light therapy system to its medical device portfolio. Its Fullerene C60 coated nanophotonic lens is a revolutionary upgrade to Photobiomodulation Therapy and makes it possible to penetrate the healing spectra of light infinitely into our tissues and organs. In comparison, the previous depth of light penetration was about 6mm. We truly strive to educate the public as well as contribute to a better quality of life for everyone. We are proud of the fact that we have raised the level of quality high by becoming an importer and distributor of HYDROGEN WATER DEVICES with certified medical quality and highest level of performance. /link/